Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
July 28 2015 - 4:15PM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced that Pamela J. Craig, retired chief
financial officer of Accenture, and Dr. Paul B. Rothman, dean of
the medical faculty, vice president for medicine of The Johns
Hopkins University and chief executive officer of Johns Hopkins
Medicine, will join the company’s board of directors, effective
Sept. 1, 2015.
The addition expands the Merck board to 14 members. Ms. Craig
will serve as a member of the company’s audit committee, and Dr.
Rothman will serve as a member of the company’s research committee.
They will both stand for election by the company’s shareholders in
May 2016.
“We are pleased to welcome Pamela Craig and Dr. Paul Rothman to
the Merck board. Each brings a tremendous wealth of experience and
expertise in their respective fields,” said Kenneth C. Frazier,
chairman and chief executive officer, Merck. “We are confident that
their contributions and insights will further strengthen the
board.”
Ms. Craig served as the chief financial officer of Accenture, a
global management consulting, technology services and outsourcing
company, from 2006 until her retirement in 2013. During her 34
years at Accenture, she held a variety of consulting, line
management, operational and finance leadership roles. Ms. Craig is
currently a senior advisor for Teneo, a global advisory firm.
Ms. Craig is a Phi Beta Kappa graduate of Smith College and
earned an MBA from New York University. She serves as a member of
the board of directors of Akamai Technologies, a leading worldwide
provider of internet optimization services, where she also serves
as audit committee chair and as a member of the compensation
committee. She also serves as a board member and M&A committee
member of VMware, Inc., a global technology leader in
virtualization and cloud infrastructure. Additionally, Ms. Craig
serves on the board of directors and audit committee of Wal-Mart
Stores, Inc.
Dr. Rothman oversees the Johns Hopkins Health System and school
of medicine. A rheumatologist and molecular immunologist, he joined
Johns Hopkins in July 2012 after having served as dean of the
Carver College of Medicine at the University of Iowa and leader of
its clinical practice plan since 2008. He previously served as head
of internal medicine at the University of Iowa from 2004 until
2008. Prior to that, he was vice chairman for research and founding
director of the Division of Pulmonary, Allergy and Critical Care
Medicine at Columbia University College of Physicians and Surgeons,
where he joined the faculty in 1986.
Dr. Rothman is a 1980 Phi Beta Kappa graduate of the
Massachusetts Institute of Technology and earned his medical degree
from Yale University in 1984. He is a member of the American
Society for Clinical Investigation and is a fellow of the American
College of Physicians. He was elected to the council of Association
of American Physicians as a fellow of the American Association for
the Advancement of Sciences and as a member of the American
Clinical and Climatological Association.
About Merck
Today’s Merck is a global health care leader working to help the
world be well. Merck is known as MSD outside the United States and
Canada. Through our prescription medicines, vaccines, biologic
therapies and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access
to health care through far-reaching policies, programs and
partnerships. For more information, visit www.merck.com and connect
with us on Twitter, Facebook and YouTube.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2014
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150728005126/en/
MerckMedia Contacts:Lainie Keller, 908-236-5036orInvestor
Contacts:Justin Holko, 908-740-1879
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024